SNDX

Syndax Pharmaceuticals Inc · NASDAQ

Sector Health Technology
Industry Biotechnology
Website yndax.com
Employees(FY) 107
ISIN US87164F1057

Performance

+0.03%

+15.14%

-23.81%

-35.68%

+9.04%

YTD

-29.65%

Profile

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of SNDX 2025-01-31

The stock indicators reflect a neutral sentiment, with the Moving Average Score at 50 indicating a balanced outlook, while both the Oscillators and Technical Scores at 46 suggest a slight bearish inclination. Overall, the combined scores imply a cautious market environment, warranting close monitoring for potential shifts in momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SNDX

Stock Rank

Recent News & Updates

2025-01-30 07:00
Syndax Announces Participation in February Investor Conferences(PR Newswire)
2025-01-29 18:00
Syndax Announces Participation in February Investor Conferences(Prnewswire)
2025-01-16 06:29
Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease(MT Newswires)
2025-01-15 17:34
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes(PR Newswire)
2025-01-15 04:34
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes(Prnewswire)
2025-01-13 07:00
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference(PR Newswire)
2025-01-12 18:00
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference(Prnewswire)
2025-01-10 09:16
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain(Simply Wall St.)
2025-01-07 07:00
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference(PR Newswire)
2025-01-06 18:00
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference(Prnewswire)
2025-01-03 16:05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(PR Newswire)
2025-01-03 03:05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Prnewswire)
2024-12-09 07:30
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial(PR Newswire)
2024-12-08 18:30
Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial(Prnewswire)
2024-12-07 18:15
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting(PR Newswire)
2024-12-07 05:15
Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting(Prnewswire)
2024-12-04 13:32
Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?(Insider Monkey)
2024-12-03 16:05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(PR Newswire)
2024-12-03 03:05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Prnewswire)
2024-11-27 07:00
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference(PR Newswire)
2024-11-26 18:00
Syndax Announces Participation at the Citi 2024 Global Healthcare Conference(Prnewswire)
2024-11-18 07:12
Syndax secures FDA OK for new kind of leukemia drug(BioPharma Dive)
2024-11-18 06:39
FDA approves Syndax’s Revuforj to treat leukaemia(Pharmaceutical Technology)
2024-11-15 17:29
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation(PR Newswire)
2024-11-15 04:29
Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation(Prnewswire)
2024-11-14 14:16
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data(Zacks)
2024-11-13 19:00
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon(Prnewswire)
2024-11-13 13:06
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint(Pharmaceutical Technology)
2024-11-13 07:21
Syndax’s revumenib meets primary results in AML trial(TipRanks)
2024-11-12 13:07
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer(Benzinga)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.